Platelets are a major player and represent a therapeutic opportunity in systemic lupus erythematosus
M Robert, M Scherlinger - Joint Bone Spine, 2024 - Elsevier
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune
dysregulation and organ injury with a premature mortality due to cardiovascular diseases …
dysregulation and organ injury with a premature mortality due to cardiovascular diseases …
[HTML][HTML] Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELY
MD Russell, J Massey, E Roddy… - The Lancet …, 2023 - thelancet.com
Background Gout is the most prevalent inflammatory arthritis, yet one of the worst managed.
Our objective was to assess how the COVID-19 pandemic impacted incidence and quality of …
Our objective was to assess how the COVID-19 pandemic impacted incidence and quality of …
Barriers to the diagnosis of early inflammatory arthritis: a literature review
L Saraiva, C Duarte - Open Access Rheumatology: Research and …, 2023 - Taylor & Francis
The early identification of patients with inflammatory arthritis and their referral to
rheumatologists in order to establish a diagnosis and to start treatment plays a crucial role in …
rheumatologists in order to establish a diagnosis and to start treatment plays a crucial role in …
OpenSAFELY: The impact of COVID‐19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate
Aims The COVID‐19 pandemic created unprecedented pressure on healthcare services.
This study investigates whether disease‐modifying antirheumatic drug (DMARD) safety …
This study investigates whether disease‐modifying antirheumatic drug (DMARD) safety …
The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of …
Objectives: The aim of the Severe Psoriatic arthritis–Early intervEntion to control Disease
trial is to compare outcomes in psoriatic arthritis (PsA) patients with poor prognostic factors …
trial is to compare outcomes in psoriatic arthritis (PsA) patients with poor prognostic factors …
[HTML][HTML] The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19
K Bechman, ACA Green, MD Russell, Z Yang… - Journal of Infection, 2024 - Elsevier
Objective This proof-of-principle pharmacovigilance study used Electronic Health Record
(EHR) data to examine the safety of sotrovimab, paxlovid and molnupiravir in prehospital …
(EHR) data to examine the safety of sotrovimab, paxlovid and molnupiravir in prehospital …
Incidence of clinically diagnosed psoriatic arthritis in Sweden
S Exarchou, D Di Giuseppe, E Klingberg… - The Journal of …, 2024 - jrheum.org
Objective Prior incidence estimates of psoriatic arthritis (PsA) vary considerably. We aimed
to assess the annual incidence of clinically diagnosed PsA among adults in Sweden 2014 …
to assess the annual incidence of clinically diagnosed PsA among adults in Sweden 2014 …
[HTML][HTML] Trends in Gout Incidence and Management during the COVID-19 Pandemic: A Nationwide Study in England via OpenSAFELY
MD Russell, J Massey, E Roddy… - The Lancet …, 2023 - ncbi.nlm.nih.gov
Background Gout is the most prevalent inflammatory arthritis, yet one of the worst managed.
Our objective was to assess how the COVID-19 pandemic impacted on incidence and care …
Our objective was to assess how the COVID-19 pandemic impacted on incidence and care …
[HTML][HTML] Disease-Modifying Medications in Patients with Rheumatoid Arthritis in the USA: Trends from 2016 to 2021
SK Peasah, ECS Swart, Y Huang, SL Kane-Gill… - Drugs-Real World …, 2024 - Springer
Background Disease-modifying anti-rheumatic drugs (DMARDs), since their introduction in
1990, have revolutionized the management of rheumatoid arthritis. Newer DMARDs have …
1990, have revolutionized the management of rheumatoid arthritis. Newer DMARDs have …
Trust performance in managing inflammatory arthritis over time in England and Wales: a latent class analysis approach
Z Yang, N Arumalla, E Alveyn… - … Advances in Practice, 2024 - academic.oup.com
Objectives To evaluate trust-level performance in time to initiation of DMARD therapy in
patients with early inflammatory arthritis (EIA), with identification of the change in …
patients with early inflammatory arthritis (EIA), with identification of the change in …